Image

Europe Diabetic Assays Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Dec 2019
  • Europe
  • 350 Pages
  • No of Tables: 121
  • No of Figures: 35
  • Pharmaceutical
  • Published Report
  • Dec 2019
  • Europe
  • 350 Pages
  • No of Tables: 121
  • No of Figures: 35

By Type (Assays, Devices, Consumables), Disease Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), Deployment (Automated, Manual), End User (Hospitals, Clinics, Diagnostic Laboratories, Academic Institutes, Others), Distribution Channel (Direct, Indirect), Country (Germany, France, Italy, U.K., Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe), Market Trends and Forecast to 2027

Europe Diabetic Assays Market

Market Analysis and Insights: Europe Diabetic Assays Market

Europe diabetic assays market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with the CAGR of 3.9% in the forecast period of 2020 to 2027and expected to reach USD 1,184.48 million by 2027 from USD 883.60 million in 2019. Growing prevalence of diabetes and high diabetes reimbursement of diabetes are the factors for the market growth.

Diabetes products cost has increased by 26% from 2012 to 2017 after taking into consideration various factor such as economic and inflation factors. This is accredited to the increasing prevalence of diabetes and per person cost due to these reasons government in various countries has established government and non-organization to help patients in diabetes management.

Growing government awareness towards the identification of diabetes among geriatric and young population and high reimbursement policies services provided by the government and private organizations are accelerating the population towards the diagnosis of diabetes and focusing towards their treatment.

For instance,   

In Ireland, Ministry of Health Simon Harris is providing reimbursement for diabetes reimbursement through Health Service Executive under the HSE Medicines Management Programme (MMP) through National Clinical Programme for Diabetes. Reimbursement has increased demand of diabetic strips for this availability of reimbursement for diabetic strips is working as driver for diabetic assays market

This diabetic assays market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Diabetic Assays Market Scope and Market Size

Europe diabetic assays market is segmented of the basis of type, disease type, deployment, end- user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the market is segmented device, assays and consumables. In 2020, the assays segment is dominating the market due to advancement in the assays to provide rapid detection by using diabetes analysers, for instance, In April 2016, Abnova Corporation (Taiwan) received an approval for CE marking for its new application for Abnova Personal A1c Diabetes HbA1c Rapid Test Kit. Through this approval, the company will be able to offer new product line in professional range in European Countries.
  • The advancement in assays such as quick identification of diabetes through blood samples major vendors augmented the market growth of diabetes assays market. For instance,         In October 2019, Abbott (U.S.) and Tandem Diabetes Care, Inc (U.S.) developed integrated diabetes solutions that combine one of the leading technologies which are glucose sensing, manufactured by Abbott with innovative insulin delivery systems of Tandem in the order to provide more preferences for people to be able to manage their diabetes. The self-detection and monitoring of the diabetes and awareness towards the healthy life style penetrates the growth of the diabetes assays market.
  • On the basis of disease type, the market is segmented into type 1 diabetes, type 2 diabetes and gestational diabetes. In 2020, type 2 diabetes segments is dominating and growing in the Europe diabetic assays market as the occurrence of type 2 diabetes are more which accounts for more than 80% in American population.  For instance, according to Centers for Disease Control and Prevention (CDC), in 2018, the total diabetes cases accounts around 30 million in total American population in which 95 to 90% of population was diagnosed with Type 2 diabetes. The type 2 diabetes was highly diagnosed among younger population due to unhealthy routine around 75% of younger population in American region is close to type 2 diabetes.
  • On the basis of deployment, the market is segmented into automated and manual. The automated diabetic assays are the most advanced deployment for providing powerful efficiency as well productivity for better medical information to clinicians, which is leading the automated devices market. The company Siemens Healthineers (Germany) offers ADVIA Chemistry XPT System and ADVIA 1800 Chemistry System used in immunoassays and also used in the detection of diabetes.
  • On the basis of end user, the market is segmented into hospitals, clinics, diagnostic laboratories, academic institutes and others. In 2020, hospitals segment is dominating as well as growing in the market as the diabetes assays due to the wide availability of diagnostic procedures of diabetes in hospitals laboratories which is performed under trained professionals for analysis of blood glucose level of diabetic patient.
  • On the basis of distribution channel, the market is segmented into direct and indirect. In 2020, the direct segment is dominating the Europe diabetic assays market and is growing with the highest CAGR as the hospitals, established diagnostic laboratories and among others prefer the product supply directly from the manufacturers as the offering through this mode are lower in cost and are at discounted prices. Further, massive supply of such product is directly maintained by the manufacturer itself and due to these reasons this segment is leading in the forecasted period.

Diabetic Assays Market Country Level Analysis

Europe diabetic assays market is analysed and market size information is provided by country, by type, disease type, deployment, end- user and distribution channel as referenced above.

The countries covered in the diabetic assays market report are Germany, France, Italy, U.K., Spain, Russia, Netherlands, Switzerland, Belgium, Turkey and Rest of Europe in Europe.

Country Level Analysis, By Type

Europe dominates the diabetic assays market as the Germany is leader in diabetic assays market due to high prevalence rate and high diabetes care expenditure cost in European region.  The total healthcare expenditure due diabetes was in 2017 was around 207 billion which was estimated to reach USD 214 billion in 2045.  For instance, according to International Diabetes Federation (IDF), the total number of population with diabetes was around 9,102,395, whereas diabetes cost per person was around USD 6,234.93. The overall expenditure and high prevalence rate focused towards the diagnosis of diabetes and accelerating the growth of diabetes assays in forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Awareness towards the Detection of Diabetes and New Technology Penetration

Europe diabetic assays market also provides you with detailed market analysis for every country growth in automotive industry with diabetic assays sales, assays and devices sales, impact of technological development in assays and changes in regulatory scenarios with their support for the diabetic assays market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Diabetic Assays Market Share Analysis

Diabetic assays market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Europe diabetic assays market.

The major players covered in the report are Abbott, Danaher, Merck KGaA, SIEMENS HEALTHINEERS AG, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., EKF Diagnostics, DRG INSTRUMENTS GMBH, PTS Diagnostics, Ortho Clinical Diagnostics, Medipan GmbH, Diagnostic Automation/Cortez Diagnostics Inc., Diazyme Laboratories, Inc., Ethos Biosciences, Inc., BioAssay Systems, Tosoh Corporation, Abnova Corporation, Monobind Inc, ORGENTEC Diagnostika GmbH, ALPCO., among other domestic and regional players. Diabetic assays market share data is available for Europe separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product developments are also initiated by the companies worldwide which are also accelerating the Europe diabetic assays market.

For instance,

  • In February 2018, Merck KGaA (Germany) has set up a new production unit for the life sciences business in Mumbai, India. The unit occupies 10 acres of space plus gross domestic product storage for future growth, thereby reducing lead times along with improving inventory availability. This manufacturing unit will expand the business growth as well as overall revenue of the company.
  • In October 2017, EKF Diagnostics Holdings plc (U.K.) and Ortho Clinical Diagnostics have reported a partnership allowing Ortho consumers to obtain beta-hydroxybutyrate (BHB) screening. A significant predictor for ketoacidosis and its main cause, diabetic ketoacidosis (DKA) is used in combination with clinical results and other laboratory tests. The high-quality fully automated system is now valid for the VITROS 4600 and the Integrated VITROS 5600 Chemical System from Ortho. This collaboration expands the product portfolio of EKF Diagnostics Holdings plc and increases its market share..

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for diabetic assays through expanded model range.


SKU-
Why Choose Us


Frequently Asked Questions